Selected article for: "acute disease management and respiratory syndrome"

Author: Curigliano, G.; Banerjee, S.; Cervantes, A.; Garassino, M.C.; Garrido, P.; Girard, N.; Haanen, J.; Jordan, K.; Lordick, F.; Machiels, J.P.; Michielin, O.; Peters, S.; Tabernero, J.; Douillard, J.Y.; Pentheroudakis, G.
Title: Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
  • Cord-id: y2lbjsk6
  • Document date: 2020_7_31
  • ID: y2lbjsk6
    Snippet: We established an international consortium to review and discuss relevant clinical evidence in order to develop expert consensus statements related to cancer management during the severe acute respiratory syndrome coronavirus 2-related disease (COVID-19) pandemic. The steering committee prepared 10 working packages addressing significant clinical questions from diagnosis to surgery. During a virtual consensus meeting of 62 global experts and one patient advocate, led by the European Society for
    Document: We established an international consortium to review and discuss relevant clinical evidence in order to develop expert consensus statements related to cancer management during the severe acute respiratory syndrome coronavirus 2-related disease (COVID-19) pandemic. The steering committee prepared 10 working packages addressing significant clinical questions from diagnosis to surgery. During a virtual consensus meeting of 62 global experts and one patient advocate, led by the European Society for Medical Oncology, statements were discussed, amended and voted upon. When consensus could not be reached, the panel revised statements until a consensus was reached. Overall, the expert panel agreed on 28 consensus statements that can be used to overcome many of the clinical and technical areas of uncertainty ranging from diagnosis to therapeutic planning and treatment during the COVID-19 pandemic.

    Search related documents:
    Co phrase search for related documents
    • ab antibody and abs presence: 1
    • ab antibody and acid amplification: 1, 2
    • ab antibody and acute concurrent infection: 1
    • ab antibody and acute infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • ab antibody and acute phase: 1
    • ab antibody and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • ab antibody and local control: 1
    • ab antibody and longitudinal study: 1
    • ab antibody and low molecular: 1
    • ab antibody and lung cancer: 1, 2